Skip to main content
Premium Trial:

Request an Annual Quote

CyVek Raises $5.5M in Preparation of Platform Launch

NEW YORK (GenomeWeb News) – CyVek today said that it has raised $5.5 million in a Series D financing round.

The funding will go toward building an infrastructure to commercialize the company's multiplex immunoassay technology called CyPlex, which uses a microfluidic cartridge for analyzing multiple biomarkers from small amounts of biological samples. CyPlex will be used initially for life sciences, drug discovery, and clinical research applications, the Wallingford, Conn.-based company said.

CyVek did not respond to a request for additional information about its commercialization plans.

Connecticut Innovations and private investors participated in the round, CyVek said.

"The funding provided by our investors will enable us to complete development-related activities and put together the team and infrastructure required to commercialize," Per Hellsund, founder, president and CEO of CyVek, said in a statement.

CyVek was founded in 2010 and raised $2 million in a private equity offering then. Last May, the firm raised $2 million in a Series C round.

The Scan

Driving Malaria-Carrying Mosquitoes Down

Researchers from the UK and Italy have tested a gene drive for mosquitoes to limit the spread of malaria, NPR reports.

Office Space to Lab Space

The New York Times writes that some empty office spaces are transforming into lab spaces.

Prion Pause to Investigate

Science reports that a moratorium on prion research has been imposed at French public research institutions.

Genome Research Papers on Gut Microbe Antibiotic Response, Single-Cell RNA-Seq Clues to Metabolism, More

In Genome Research this week: gut microbial response to antibiotic treatment, approach to gauge metabolic features from single-cell RNA sequencing, and more.